307 related articles for article (PubMed ID: 17877649)
1. Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.
Palmer AJ; Valentine WJ; Ray JA
Int J Clin Pract; 2007 Oct; 61(10):1626-33. PubMed ID: 17877649
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.
Palmer AJ; Annemans L; Roze S; Lamotte M; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH
Diabetes Care; 2004 Aug; 27(8):1897-903. PubMed ID: 15277414
[TBL] [Abstract][Full Text] [Related]
3. [Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy].
Palmer AJ; Roze S; Rodby RA; Valentine WJ; Ritz E; Lehnert H
Dtsch Med Wochenschr; 2006 Aug; 131(31-32):1721-6. PubMed ID: 16868875
[TBL] [Abstract][Full Text] [Related]
4. A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
Palmer AJ; Valentine WJ; Tucker DM; Ray JA; Roze S; Annemans L; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH; Laville M
Curr Med Res Opin; 2006 Nov; 22(11):2095-100. PubMed ID: 17076969
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective.
Coyle D; Rodby R; Soroka S; Levin A; Muirhead N; de Cotret PR; Chen R; Palmer A
Clin Ther; 2007 Jul; 29(7):1508-23. PubMed ID: 17825702
[TBL] [Abstract][Full Text] [Related]
6. Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.
Palmer AJ; Roze S; Valentine WJ; Ray JA; Frei A; Burnier M; Hess B; Spinas GA; Brändle M
Swiss Med Wkly; 2006 May; 136(21-22):346-52. PubMed ID: 16779715
[TBL] [Abstract][Full Text] [Related]
7. An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting.
Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Bilous RW
J Hum Hypertens; 2004 Oct; 18(10):733-8. PubMed ID: 15116142
[TBL] [Abstract][Full Text] [Related]
8. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.
Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Cordonnier DJ
Nephrol Dial Transplant; 2003 Oct; 18(10):2059-66. PubMed ID: 13679481
[TBL] [Abstract][Full Text] [Related]
9. [Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Ritz E
Dtsch Med Wochenschr; 2004 Jan; 129(1-2):13-8. PubMed ID: 14703575
[TBL] [Abstract][Full Text] [Related]
10. [Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland].
Frei A; Palmer AJ; Burnier M; Hess B
Praxis (Bern 1994); 2006 Mar; 95(11):401-8. PubMed ID: 16570646
[TBL] [Abstract][Full Text] [Related]
11. [Cost-efectiveness of Ibersartan in type II diabetic nephropathy with hypertension. A Spanish perspective].
Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; de Alvaro F;
Nefrologia; 2004; 24(3):231-8. PubMed ID: 15283313
[TBL] [Abstract][Full Text] [Related]
12. Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria.
Palmer AJ; Annemans L; Roze S; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH; De Alvaro F
Kidney Int Suppl; 2005 Jan; (93):S52-4. PubMed ID: 15613069
[TBL] [Abstract][Full Text] [Related]
13. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Lewis EJ; Lewis JB
Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
[TBL] [Abstract][Full Text] [Related]
14. Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis.
Palmer AJ; Valentine WJ; Ray JA; Roze S; Muszbek N
Eur J Health Econ; 2007 Jun; 8(2):161-8. PubMed ID: 17237927
[TBL] [Abstract][Full Text] [Related]
15. Health economics studies assessing irbesartan use in patients with hypertension, type 2 diabetes, and microalbuminuria.
Palmer AJ; Rodby RA
Kidney Int Suppl; 2004 Nov; (92):S118-20. PubMed ID: 15485404
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy.
Rodby RA; Chiou CF; Borenstein J; Smitten A; Sengupta N; Palmer AJ; Roze S; Annemans L; Simon TA; Chen RS; Lewis EJ;
Clin Ther; 2003 Jul; 25(7):2102-19. PubMed ID: 12946554
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies.
Palmer AJ; Tucker DM; Valentine WJ; Roze S; Gabriel S; Cordonnier DJ
Nephrol Dial Transplant; 2005 Jun; 20(6):1103-9. PubMed ID: 15855214
[TBL] [Abstract][Full Text] [Related]
18. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I;
N Engl J Med; 2001 Sep; 345(12):851-60. PubMed ID: 11565517
[TBL] [Abstract][Full Text] [Related]
19. An Asian regional analysis of cost-effectiveness of early irbesartan treatment versus conventional antihypertensive, late amlodipine, and late irbesartan treatments in patients with type 2 diabetes, hypertension, and nephropathy.
Annemans L; Demarteau N; Hu S; Lee TJ; Morad Z; Supaporn T; Yang WC; Palmer AJ
Value Health; 2008; 11(3):354-64. PubMed ID: 17888064
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada.
Coyle D; Rodby RA
Can J Cardiol; 2004 Jan; 20(1):71-9. PubMed ID: 14968145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
